These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30350561)

  • 1. Long-term efficacy and safety of adalimumab on a severe case of hidradenitis suppurativa.
    Caposiena Caro RD; Cannizzaro MV; DI Raimondo C; DI Matteo E; Botti E; Rossi P; Bianchi L
    Ital J Dermatol Venerol; 2021 Feb; 156(1):101-102. PubMed ID: 30350561
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab (Humira°) and hidradenitis suppurativa.
    Prescrire Int; 2017 Apr; 26(181):94-96. PubMed ID: 30730659
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction.
    Company-Quiroga J; Alique-García S; Martínez-Morán C; Khedaoui R; Romero-Maté A; Borbujo J
    Indian J Dermatol Venereol Leprol; 2019; 85(4):422-425. PubMed ID: 31115357
    [No Abstract]   [Full Text] [Related]  

  • 5. Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa.
    Canal Garcia E; Vargas Ramos JDP; Aguayo Ortiz R
    Australas J Dermatol; 2020 Nov; 61(4):e448-e449. PubMed ID: 32567672
    [No Abstract]   [Full Text] [Related]  

  • 6. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa.
    Sugaya M; Ishii M; Takahashi-Shishido N; Ichimura Y; Morimura S
    J Dermatol; 2021 Apr; 48(4):e163-e164. PubMed ID: 33502014
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab-Induced Neutropenia in a Man With Hidradenitis Suppurativa.
    Rueda Carnero JM; Nieto Rodríguez D; de Lucas Laguna R; Feito Rodríguez M
    Actas Dermosifiliogr (Engl Ed); 2020 Apr; 111(3):273-274. PubMed ID: 31980127
    [No Abstract]   [Full Text] [Related]  

  • 9. Candida Esophagitis Associated With Adalimumab for Hidradenitis Suppurativa.
    Nazarian RS; Farberg AS; Smith BL
    Cutis; 2021 Mar; 107(3):E6-E7. PubMed ID: 33956612
    [No Abstract]   [Full Text] [Related]  

  • 10. Tildrakizumab for the treatment of hidradenitis suppurativa in patients previously treated with adalimumab: a 30-month experience.
    Koszegi B; Wilson A; Stone C; Satgé F; Cowan TL; Murrell DF
    Clin Exp Dermatol; 2023 Oct; 48(11):1266-1269. PubMed ID: 37434310
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience.
    Bettoli V; Manfredini M; Calamo G; Forconi R; Bencivelli D; Mantovani L; Pellacani G; Corazza M
    Dermatol Ther; 2018 Nov; 31(6):e12737. PubMed ID: 30295378
    [No Abstract]   [Full Text] [Related]  

  • 13. New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab.
    Phan K; Charlton O; Smith SD
    Dermatol Ther; 2020 May; 33(3):e13347. PubMed ID: 32239739
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa.
    Turk D; Vellaichamy G; Lyons AB; Parks-Miller A; Nelson T; Meysami A; Hamzavi IH
    Int J Dermatol; 2020 Mar; 59(3):e73-e74. PubMed ID: 31633193
    [No Abstract]   [Full Text] [Related]  

  • 15. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa.
    Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F
    Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
    Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
    JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
    N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting.
    Odorici G; Pacetti L; Forconi R; Schettini N; Zedde P; Corazza M; Bettoli V
    J Dermatolog Treat; 2022 Jun; 33(4):2063-2067. PubMed ID: 33843413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.